Latest Articles and Analysis

Formulary cuts, fibrosis staging requirements making a comeback, and the near-disappearance of HCV charitable assistance programs — CANN's Q3 2026 HIV/HCV Co-Infection Watch maps a deteriorating access landscape for people living with HIV/HCV co-infection.

Congress has introduced the most ambitious federal hepatitis C elimination bill in a generation — $9.8 billion, no cost-sharing, and a delivery investment long overdue. The procurement model at its center could undermine the access it promises.

For the first time, a finite course of therapy has produced a functional cure for chronic hepatitis B in large-scale phase 3 trials, but the communities carrying the heaviest burden of this disease are also the least likely to be screened, diagnosed, or insured. Whether this milestone translates into population-level progress is a policy question, not a scientific one.

Q1 2026 Watch: HCV/HIV co-infection treatment access under evolving federal and state policies.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Q1 2025 Watch: comprehensive update on HIV/HCV co-infection treatment access across federal and state programs.

Q4 2024 Watch: HCV treatment access assessment with guidance for disaster-displaced individuals.

Call to action for community input on federal health policy initiatives.

Q3 2024 Watch monitoring HCV treatment access across ADAPs, Medicaid, Veterans programs, and assistance initiatives.

HHS proposed viral hepatitis quality measures for Medicaid and health equity implications.

Q2 2024 Watch: Prior authorization rollbacks in Medicaid HCV programs; ADAP and assistance program coverage.

Q1 2024 Watch: Pandemic Medicaid protections ended; millions lost coverage; ADAP and veterans updates.

CANN outlines organizational growth and 2024 policy priorities including state-level advocacy.

Q4 2023 Watch: Bipartisan PEPFAR reauthorization push; ADAP coverage and Medicaid updates tracked.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.